TY - JOUR
T1 - MYC oncogenes and human neoplastic disease
AU - Nesbit, Chadd E.
AU - Tersak, Jean M.
AU - Prochownik, Edward V.
N1 - Funding Information:
We apologize to our colleagues for omissions necessitated by the space constraints imposed on this review. This work was supported by NIH grant HL33741 Bhatia K, Spangler G, Hamdy N, Neri A, Brubaker G, Levin A and Macgrath I. (1995). Curr. Top. Microbiol. Immunol., 194, 389 – 398. Birrer MJ, Segal S, DeGreve JS, Kaye F, Sausville EA and Minna JD. (1988). Mol. Cell. Biol., 8, 2668 – 2673. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN and Weintraub H. (1990). Science, 250, 1149 – 1151. Blackwell TK, Huang J, Ma A, Kretzner L, Alt FW, Eisenman RN and Weintraub H. (1993). Mol. Cell. Biol., 13, 5216 – 5224. Boultwood J, Wylie FS, Williams ED and Wynford-Thomas D. (1988). Cancer Res., 48, 4073 – 4077. Bradley JF, Rothberg PG, Ladanyi M, Chaganti RS. (1993). Genes Chromo. Cancer, 7, 128 – 130. Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG, Lee CP and Evans AE. (1997). J. Neurooncol., 31, 49 – 55. Brodeur GM, Segar RC, Schwab M, Varmus HE and Bishop JM. (1984). Science, 224, 1121 – 1124. Brodeur GM, Segar RC, Schwab M, Varmus HE and Bishop JM. (1985). Prog. Clin. Biol. Res., 175, 105 – 113. Brough DE, Hofmann TJ, Ellwood KB, Townley RA and Cole MD. (1995). Mol. Cell. Biol., 15, 1536 – 1544. Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T and Wiels J. (1998). Oncogene, 16, 1603 – 1610. Caron H, Peter M, van Sluis R, Speleman F, de Kraker J, Laureys G, Michon J, Brugieres L, Voute PA, Westerveld A, Slater R, Delattre O and Versteeg R. (1995). Hum. Mol. Genet., 4, 535 – 539. Caron H, van Sluis P, deKraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA and Versteeg R. (1996). N. Engl. J. Med., 334, 225 – 230. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M and Nunez G. (1993). Am. J. Pathol., 143, 1543 – 1550. Cesarman E, Dalla-Favera R, Bentley D and Groudine M. (1987). Science, 238, 1272 – 1275.
PY - 1999/5/13
Y1 - 1999/5/13
N2 - c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we first summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite different roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in specific neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which significant and confirmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.
AB - c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we first summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite different roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in specific neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which significant and confirmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.
UR - http://www.scopus.com/inward/record.url?scp=0033551374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033551374&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1202746
DO - 10.1038/sj.onc.1202746
M3 - Review article
C2 - 10378696
AN - SCOPUS:0033551374
SN - 0950-9232
VL - 18
SP - 3004
EP - 3016
JO - Oncogene
JF - Oncogene
IS - 19
ER -